NCT03783442 2025-07-29A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaBeiGenePhase 3 Completed649 enrolled 22 charts